Review decision – July 2018

Decision to move the existing guidance to the static list

We would like to update you on the decision made regarding the review of the existing guidance on TA346: aflibercept for treating diabetic macular oedema; and TA349: dexamethasone intravitreal implant for treating diabetic macular oedema.

There is no new evidence that would warrant reconsideration of the existing recommendations. 

Consequently, NICE’s Guidance Executive has decided that TA346 and TA349 will move to the ‘static list’ of technology appraisals. Topics on the static list can be considered for review if any new evidence becomes available that is likely to lead to a change in the existing recommendations.

Review decision paper

Stakeholder matrix

This page was last updated: